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KEY MESSAGE
This study indicates that temozolomide has limited activity in mCRC selected by MGMT hypermethylation, and show for the first time that tumor MGMT methylation can change from diagnosis, decaying after several lines of treatments. This result points out the need to test baseline tumor biopsy or plasma in order to refine target selection in trials with alkylating agents performed in this setting.
Introduction
Colorectal cancer (CRC) is the third most common type of cancer in men and the second in women worldwide [1] . CRC is also the fourth leading cause of cancer deaths worldwide, accounting for 9.7% of global new cancers, with 1.4 million cases and 694,000
deaths [2] . Approximately 25% of patients have metastatic disease at diagnosis, and almost 50% of resected patients with early stage disease will eventually develop metastases, accounting for the relevant mortality rates [2] . In the last twenty years, research efforts in mCRC have led to the approval of several targeted agents in addition to standard chemotherapy, including bevacizumab [3] , cetuximab [4] , panitumumab [5] , aflibercept [6] , and regorafenib [7] . Apart from the anti-EGFR monoclonal antibodies cetuximab and panitumumab, for which RAS gene mutations have been shown to play a negative predictive role [8] , in CRC there is a lack of clinically validated biomarkers effectively directing therapy.
MGMT is a repair protein which removes alkylating groups from the O 6 -guanine in DNA. MGMT protects normal and tumor cells from this type of DNA damage, moving the alkylating group to a cysteine residual within its own protein [9, 10] . Approximately 40% of mCRC show silencing of the MGMT gene leading this to absence of the corresponding protein [11] . Due to this deficiency, the tumor cell is not able to effectively repair O 6 -methylguanine adducts, thus determining a higher frequency of G:C > A:T transitions and potentially enhancing the cytotoxic effect of alkylating agents such as temozolomide (TMZ) or dacarbazine [10, 12] .
We previously reported that objective response to dacarbazine, the intravenous form of TMZ, is confined to tumors harboring MGMT promoter hypermethylation [13] . Initial reports indicated that mCRC selected by MGMT deficiency achieved remarkable responses to TMZ [14] . Subsequent phase II studies enriched for MGMT methylation showed objective responses up to 12% [15, 16] .
We designed the present study in order to evaluate the anti-tumor activity of TMZ in mCRC after failure of standard therapies selecting patients based on MGMT promoter hypermethylation assessed in individual archival tumor (AT) samples. In addition, we explored baseline tumor biopsy (BT) and blood (liquid biopsy) as biomarkers of the actual epigenetic status of the tumor before and during therapy. . The aim of the study was to evaluate the efficacy of TMZ treatment in a molecularly selected population of mCRC patients by assessing its ability to achieve a clinically meaningful prolongation of progression-free survival (PFS) as compared to the expected outcome in this setting [7] . Patients were treated with TMZ until progression or unacceptable toxicity. Primary endpoint was PFS rate at 12 weeks, i.e. the proportion of patients known to be alive and progression free at 12 weeks or later since Methyl-BEAMing was then carried out as previously described [18] . Statistical analysis -A Fleming single-stage procedure was applied for sample size calculation [19] . The success rate was defined as the proportion of patients in a progression-free status at ≥ 12 weeks since treatment start out of the total number of treated patients. According to a recently published phase III trial in a similar patient population [7] , the PFS rate at 12 weeks of untreated patients was estimated to be approximately 15%. Therefore, a rate of 35% of patients alive and progression-free at 12
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Study design -
week (H 1 ) was identified as a meaningful improvement for the proposed TMZ single agent Table 1) .
Treatment Efficacy and Toxicity -The primary endpoint of the study was not met, since PFS rate at 12 weeks was 10.3% (CI 2.9 -24.6%). Median follow-up was 9.8 months (CI 9.46 -not reached). Median PFS was 2.6 months (CI 1.4 -2.7) (Figure 2, A) . We Hematological adverse events were the most common reason for dose modification (7 patients, 24%). Common adverse events (occurring in > 10% of patients) are reported in Table 2 . AT (p=0.6) ( Figure 3A) . However, a significant correlation was retrieved when the same analysis was performed in BT (p=0.03) ( Figure 3B ). In particular, all patients displaying tumor increase segregated below a cutoff value of 17.4% of MGMT methylation in BT.
Exploratory biomarkers analysis -
In plasma, we found that median MGMT methylation by methylBEAMing at baseline was 14.6% (range 0.0-81.0%). This value is significantly different as compared to the same method applied to AT (p=0.025 by Wilcoxon rank sum test), but not to BT (p=0.627).
Interestingly, 7 patients displayed no methylation at all in plasma (0%), mirroring the results by MSP in baseline biopsy. After 1 cycle of TMZ treatment, we found a correlation between methylation variation in plasma and tumor shrinkage (p=0.008) (Figure 4) .
Finally, we found no association between KRAS mutations assessed in AT and DCR (p=0.48).
Discussion
Three phase II clinical trials have previously assessed the clinical efficacy of alkylating agents in mCRC. All of them have assessed the role of MGMT promoter hypermethylation as a predictive biomarker of response by the analysis of archival tumor tissues [13, 15, 16] . Despite some evidence of improved disease control rate in patients with MGMT hypermethylated tumors, the role of this biomarker in mCRC remains unclear.
In the present study, we report that, in a cohort of 29 patients, all selected for MGMT promoter hypermethylation by MSP in individual archival tumor, TMZ treatment did not overcome the threshold of a meaningful PFS rate at 12 weeks of 35%, with ORR of 3.4%
and DCR of 48.3%. The innovative study design included MGMT assessment in archival tumor specimens, in biopsy of tumor at baseline and in plasma (liquid biopsy), leading to the following novel findings about the dynamic of this epigenetic biomarker.
First, we observed a previously unreported change in MGMT status occurring over time, i.e., MGMT methylation declined significantly from archival tumor samples compared to a biopsy taken at the actual moment of starting treatment with TMZ. It has been previously reported that in glioblastoma MGMT promoter methylation status can change after chemotherapy [20] , but very limited data are available for CRC [12, 21, 22] . It should be acknowledged that in our study the time between sample collection and analysis of MGMT methylation in archival tumor vs. baseline tumor biopsy was remarkably different (median 2.8 years vs. 2 days), therefore the observed reduction in MGMT methylation of the tumors may be due also to long term storage [23] . Further, we cannot exclude that sampling procedures along with tumor heterogeneity could have affected the performance of MGMT testing on tissue, thus reducing its sensitivity. Indeed, large-scale analyses addressing the issue of epigenomics heterogeneity in colorectal cancer are missing and future studies might shed light on the extent or implications of this phenomenon. As a consequence, regardless of the possible cause or explanation, we highlight that molecular screening of MGMT hypermethylation by MSP on archival tumor does not properly select a mCRC population for a biomarker-enriched design. Accordingly, we found that only the percentage of MGMT methylation in baseline tumor biopsy, but not that in archival tumor, was correlated with tumor shrinkage after TMZ treatment. However, the observed correlation was weak (R=0.24; Figure 3B ), possibly because in an advanced setting the heavy pretreatment (in present study 5 median previous lines) gives rise to multiple resistance mechanisms to DNA damaging agents, limiting sensitization by MGMT loss.
Moreover, the only patient who achieved partial response did not display MGMT methylation in baseline tumor biopsy, dictating caution in the interpretation of data.
Altogether, these findings suggest that MGMT as a biomarker should be evaluated at the time of treatment, and not relying on previous older specimens as it was done in most of published trials for mCRC [13, 15] . Only Hochhauser et al. [16] made a patients selection by using also blood-based MSP assessment at the study entry, but data of matched pairs of tissue/plasma were not provided.
Second, we analyzed MGMT methylation status in plasma to test whether liquid biopsy, being performed on a fresh blood sample collected at the time of enrolment, could overcome the previously described spatial and time-dependent variations of the biomarker.
This was performed by the quantitative assay methylBEAMing in order to study fluctuations during treatment. Given its blood-based nature, there might be a role for this test in dynamically assessing epigenetic status of MGMT by providing updated results without the need of repeated tumor biopsies. Hochhauser et al [16] previously reported an assessment of MGMT by MSP from blood in a phase II trial with miscellaneous tumor, including aereodigestive, colorectal and head-and-neck cancers. They show that 61% of patients with positive MGMT methylation by MSP in tissue did not confirm this finding in blood, even though distinct data for CRC histology were not provided. In our study, we found that plasma MGMT methylation before treatment was significantly different from that determined, with the same method, in the archival tumor, but not from that assessed on baseline tumor biopsy, confirming also in plasma the loss of MGMT methylation after time.
Interestingly, 7 patients displayed no methylation at all (0%) in plasma baseline, which could be explained by absence of DNA from tumor origin. However, five of the matched biopsies also displayed very low methylation fraction (<1%) suggesting a loss of the methylated status in the tumor. Among the 22 remaining matched pairs of baseline tumor biopsies/plasma samples (n=22), we found high sensitivity (100%) and poor specificity 
